抗血管内皮生长因子药物治疗病理性近视脉络膜新生血管的研究进展

Current Advance in the Application of Anti-vascular Endothelial Growth Factor Drugs in Pathologic Myopia Choroidal Neovascularization

脉络膜新生血管(CNV)是病理性近视(PM)患者视力损害最严重的并发症之一,不及时治疗通常会引起不可逆的中心视力丧失。近年来,抗血管内皮生长因子药物贝伐单抗、雷珠单抗、阿柏西普和康柏西普的临床应用为PM-CNV的治疗提供了新的选择,本文主要综述PM-CNV治疗研究现状、特点及可能存在的问题,为临床治疗提供支持。

Choroidal neovascularization(CNV)is one of the most serious complications of visual impairment in patients with pathological myopia(PM),which usually leads to irreversible central vision loss if left untreated.In recent years,clinical applications of anti-vascular endothelial growth factor drugs such as bevacizumab,ranibizumab,aflibercept and conbercept have provided new options for the treatment of PM-CNV.This article focuses on reviewing the current status of PM-CNV treatment research,characteristics and possible treatment problems to support clinical treatment.